[Clinical significance of serum neuron-specific enolase in non-small cell lung cancer]. 1998

H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
Department of Internal Medicine, Toneyama National Hospital, Osaka, Japan.

The present study was a retrospective analysis of serum neuron-specific enolase (NSE) assayed in 302 patients with non-small cell lung cancer (NSCLC) before treatment. Serum NSE ranged from 0.6 to 183.0 ng/ml, with a mean value of 12.2 ng/ml, and exceeded 10 ng/ml in 145 patients (48.0%). The mean levels and rate of NSE positivity in 177 patients whose tumors were categorized as small, medium and large (from the product of the maximum and perpendicular axis of the tumor on chest X-ray), were highest in the large group. There was no significant relationship between serum NSE and the response rate to anticancer chemotherapy. The survival period of the patients with elevated serum NSE (median, 5.7 months) was significantly shorter, than those with normal serum NSE levels (median, 12.1 months). Serum NSE is of prognostic significance in a multivariate analysis (p < 0.01), but not predictive of response to chemotherapy in NSCLC.

UI MeSH Term Description Entries
D008175 Lung Neoplasms Tumors or cancer of the LUNG. Cancer of Lung,Lung Cancer,Pulmonary Cancer,Pulmonary Neoplasms,Cancer of the Lung,Neoplasms, Lung,Neoplasms, Pulmonary,Cancer, Lung,Cancer, Pulmonary,Cancers, Lung,Cancers, Pulmonary,Lung Cancers,Lung Neoplasm,Neoplasm, Lung,Neoplasm, Pulmonary,Pulmonary Cancers,Pulmonary Neoplasm
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009367 Neoplasm Staging Methods which attempt to express in replicable terms the extent of the neoplasm in the patient. Cancer Staging,Staging, Neoplasm,Tumor Staging,TNM Classification,TNM Staging,TNM Staging System,Classification, TNM,Classifications, TNM,Staging System, TNM,Staging Systems, TNM,Staging, Cancer,Staging, TNM,Staging, Tumor,System, TNM Staging,Systems, TNM Staging,TNM Classifications,TNM Staging Systems
D010751 Phosphopyruvate Hydratase A hydro-lyase that catalyzes the dehydration of 2-phosphoglycerate to form PHOSPHOENOLPYRUVATE. Several different isoforms of this enzyme exist, each with its own tissue specificity. Enolase,Neuron-Specific Enolase,2-Phospho-D-Glycerate Hydro-Lyase,2-Phospho-D-Glycerate Hydrolase,2-Phosphoglycerate Dehydratase,Enolase 2,Enolase 3,Muscle-Specific Enolase,Nervous System-Specific Enolase,Non-Neuronal Enolase,alpha-Enolase,beta-Enolase,gamma-Enolase,2 Phospho D Glycerate Hydro Lyase,2 Phospho D Glycerate Hydrolase,2 Phosphoglycerate Dehydratase,Dehydratase, 2-Phosphoglycerate,Enolase, Muscle-Specific,Enolase, Nervous System-Specific,Enolase, Neuron-Specific,Enolase, Non-Neuronal,Hydratase, Phosphopyruvate,Hydro-Lyase, 2-Phospho-D-Glycerate,Muscle Specific Enolase,Nervous System Specific Enolase,Neuron Specific Enolase,Non Neuronal Enolase,System-Specific Enolase, Nervous,alpha Enolase,beta Enolase,gamma Enolase
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002289 Carcinoma, Non-Small-Cell Lung A heterogeneous aggregate of at least three distinct histological types of lung cancer, including SQUAMOUS CELL CARCINOMA; ADENOCARCINOMA; and LARGE CELL CARCINOMA. They are dealt with collectively because of their shared treatment strategy. Carcinoma, Non-Small Cell Lung,Non-Small Cell Lung Cancer,Non-Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinoma,Nonsmall Cell Lung Cancer,Carcinoma, Non Small Cell Lung,Carcinomas, Non-Small-Cell Lung,Lung Carcinoma, Non-Small-Cell,Lung Carcinomas, Non-Small-Cell,Non Small Cell Lung Carcinoma,Non-Small-Cell Lung Carcinomas
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
June 1992, Nihon Kyobu Shikkan Gakkai zasshi,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
January 2008, Anticancer research,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
April 1988, Taiwan yi xue hui za zhi. Journal of the Formosan Medical Association,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
May 1994, Internal medicine (Tokyo, Japan),
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
October 1995, Japanese journal of clinical oncology,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
December 1988, British journal of cancer,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
June 1988, Chest,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
January 2002, Pneumonologia i alergologia polska,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
January 1988, Rinsho hoshasen. Clinical radiography,
H Kimura, and T Yamaguchi, and K Nishino, and M Nakagawa, and S Yokota, and H Nishikawa, and M Ito, and T Ogura
February 1999, Danish medical bulletin,
Copied contents to your clipboard!